Q-omics provides the consensus-scored TOB2 profile across patient tissues and cancer cell-line models. TOB2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TOB2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TOB2 RNA expression shows 19,370 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where TOB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOB2 survival associations across molecular data types. TOB2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOB2 RNA expression–survival associations across cancer types. High TOB2 expression shows unfavorable associations in ACC, COAD, UVM and CESC, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TOB2 RNA expression.
This table summarizes TOB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TOB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOB2 shows lower tumor expression in THCA, KICH, KIRP and LUAD and higher tumor expression in LIHC and HNSC. The THCA box plot shows higher TOB2 RNA expression in normal versus tumor tissue (log2 FC = −0.730, t-test p < 0.001).
This table shows molecular features associated with TOB2 in patient tissues and cancer cell lines. In patient samples, TOB2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TOB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
